Medicare and Medicaid place restrictions on new Alzheimer’s drug, Aduhelm (aducanumab)

Sources:

When Aduhelm arrived in 2021, it carried something families affected by Alzheimer’s disease had been waiting nearly two decades to hear: a new treatment had received approval from the U.S. Food and Drug Administration. It was not simply another medication designed to manage symptoms. Aduhelm, also known as aducanumab-avwa, targeted amyloid-beta plaques, one of the biological features associated with Alzheimer’s disease.

Then came the catchor, more accurately, a filing cabinet full of catches.

The FDA’s accelerated approval was based on the drug’s ability to reduce amyloid plaques rather than definitive evidence that it meaningfully slowed memory loss or preserved daily functioning. Aduhelm’s two major clinical trials produced conflicting results, the treatment carried potentially serious safety risks, and its original annual list price was a wallet-rattling $56,000 before Biogen cut it in half.

Faced with uncertain benefits, substantial monitoring requirements, and potentially enormous public costs, the Centers for Medicare & Medicaid Services issued an unusually restrictive national Medicare coverage policy. Medicaid’s position was more complicated: state programs generally had drug-coverage obligations, but they could apply clinical criteria, prior authorization, and other utilization controls. For people eligible for both Medicare and Medicaid, the question of which program paid became particularly important.

The result was a historic clash between regulatory approval and insurance coveragetwo decisions that sound similar but answer very different questions.

What was Aduhelm, and why did its approval matter?

Aduhelm was a laboratory-produced monoclonal antibody administered through an intravenous infusion approximately once every four weeks. It was developed for people in the early symptomatic stages of Alzheimer’s disease, including mild cognitive impairment caused by Alzheimer’s and mild Alzheimer’s dementia.

The medication was designed to bind to aggregated forms of amyloid beta and help remove amyloid plaques from the brain. Researchers have long investigated whether reducing these plaques can slow the chain of biological changes associated with Alzheimer’s disease.

On June 7, 2021, the FDA granted Aduhelm accelerated approval. That pathway allows the agency to approve a treatment for a serious condition based on a “surrogate endpoint”a measurable biological change reasonably likely to predict clinical benefitwhile requiring the manufacturer to complete a confirmatory study.

In Aduhelm’s case, the surrogate endpoint was amyloid-plaque reduction. The unresolved question was whether removing those plaques produced a sufficiently meaningful improvement in how patients thought, remembered, communicated, and functioned.

Sources:

Two major trials told different stories

Aduhelm’s pivotal phase 3 studies, EMERGE and ENGAGE, were designed similarly but did not deliver matching conclusions. EMERGE met its primary endpoint in the high-dose group and suggested a modest slowing of clinical decline. ENGAGE did not meet its primary endpoint.

That inconsistency became the thundercloud hanging over nearly every later argument. Supporters believed the positive study, plaque reduction, and urgent need for disease-modifying treatment justified access. Critics argued that one unsuccessful trial could not be waved away like an inconvenient restaurant receipt.

The FDA ultimately concluded that amyloid reduction was reasonably likely to predict clinical benefit, even though the clinical evidence itself remained uncertain. A post-approval trial was supposed to verify whether Aduhelm truly helped patients. Biogen later terminated that study when it discontinued the program.

Sources:

Why Medicare restricted Aduhelm coverage

FDA approval determines whether a medicine may be legally marketed in the United States. Medicare coverage determines whether the federal insurance program will pay for it under specific circumstances. Approval does not automatically require unrestricted Medicare coverage.

In April 2022, CMS finalized a National Coverage Determination for monoclonal antibodies directed against amyloid in Alzheimer’s disease. For drugs receiving accelerated approval, including Aduhelm, Medicare coverage was limited to patients participating in qualifying randomized controlled trials. Those trials had to be approved by the FDA, supported by the National Institutes of Health, or otherwise meet CMS requirements.

This approach is known as coverage with evidence development, or CED. In plain English, Medicare agreed to pay only while additional evidence was being collected in an approved research setting.

CMS concluded that the existing evidence did not establish that Aduhelm was reasonable and necessary for broad use among Medicare beneficiaries. The agency was especially concerned about uncertain clinical benefit, differences between trial participants and the wider Medicare population, and safety monitoring.

Sources:

Traditional approval created a different pathway

The 2022 policy covered two categories differently. Anti-amyloid antibodies with accelerated approval were restricted to qualifying randomized trials. Drugs that later received traditional FDA approval could be covered in CMS-approved prospective comparative studies, including registries designed to collect real-world information.

This distinction became important when Leqembi received traditional FDA approval in July 2023. CMS then provided broader Medicare coverage when clinicians and patients participated in an approved registry. The same general coverage framework later applied to other traditionally approved anti-amyloid treatments.

Therefore, the policy was not simply “Medicare refuses to cover Alzheimer’s drugs.” It tied the breadth of coverage to the strength and type of evidence supporting each treatment.

Sources:

Safety monitoring was a major part of the decision

Aduhelm could cause amyloid-related imaging abnormalities, commonly shortened to ARIA. These abnormalities include temporary brain swelling or fluid accumulation, known as ARIA-E, and small areas of bleeding or iron deposits, known as ARIA-H.

In an integrated analysis of participants receiving the highest Aduhelm dose in EMERGE and ENGAGE, approximately 41% experienced some form of ARIA. ARIA-E occurred in about 35%, although most cases did not produce noticeable symptoms. When symptoms occurred, they could include headache, confusion, dizziness, nausea, visual changes, or difficulty walking.

Because ARIA may be invisible without imaging, treatment required baseline and follow-up MRI scans. Clinicians also needed experience recognizing early Alzheimer’s disease, interpreting brain imaging, managing infusion therapy, and deciding when treatment should be paused.

That infrastructure is easier to find near a large academic medical center than in a rural community several hours from the nearest memory clinic. Coverage was therefore only one barrier. Patients also needed specialists, infusion appointments, imaging facilities, transportation, caregiver support, and repeated clinical assessments.

Sources:

How Medicaid coverage differed from Medicare

The phrase “Medicare and Medicaid restrictions” can be misleading because the two programs did not issue identical national rules.

Medicare’s policy was a formal nationwide coverage determination. Medicaid, by contrast, is jointly funded by federal and state governments and administered through individual state programs. Under the Medicaid Drug Rebate Program, participating state Medicaid programs generally must cover covered outpatient drugs made by manufacturers that have rebate agreements with the federal government.

That obligation did not mean every prescription received an automatic green light. States could use prior authorization, medical-necessity reviews, diagnostic requirements, specialist-prescribing rules, dosing limits, documentation standards, and safety criteria. Coverage details could therefore vary by state and delivery system.

MACPAC, the nonpartisan commission that advises Congress on Medicaid, noted that state Medicaid programs were generally required to cover Aduhelm for eligible beneficiaries. Policymakers nevertheless worried that Medicare’s narrow decision might shift costs toward Medicaid, particularly for people enrolled in both programs.

Sources:

What happened to people eligible for both programs?

Many older adults and people with disabilities qualify for both Medicare and Medicaid. These individuals are known as dual-eligible beneficiaries.

For Medicare-covered medical services and physician-administered drugs, Medicare is ordinarily the primary payer. Medicaid may help with premiums, deductibles, coinsurance, or other services depending on the beneficiary’s eligibility category and state rules.

CMS clarified that when Medicare did not cover Aduhelm outside the conditions of its national policy, Medicaid was not automatically required to step in and pay as though Medicare did not exist. This prevented the Medicare restriction from becoming a simple invoice-forwarding exercise in which a state Medicaid program received the entire bill.

Even so, the interaction between the programs remained difficult for families to understand. Terms such as “dual eligibility,” “Part B,” “prior authorization,” and “coverage with evidence development” are not exactly the warm conversational language most people hope to encounter after an Alzheimer’s diagnosis.

The cost debate extended far beyond one patient

Biogen initially set Aduhelm’s annual list price at approximately $56,000 for a maintenance-dose patient. In December 2021, the company reduced the price to $28,200 per year. That figure still excluded the cost of diagnostic testing, physician visits, infusion services, MRI monitoring, management of complications, and transportation.

Before Medicare announced its restrictive final policy, federal officials had prepared for the possibility of substantial Aduhelm spending. The standard Medicare Part B premium rose from $148.50 per month in 2021 to $170.10 in 2022. CMS said roughly half of that increase was associated with contingency reserves for potentially higher spending on Aduhelm.

Because nearly every Part B enrollee pays a monthly premium, the financial consequences could have reached millions of beneficiaries who would never receive the drug. After coverage was restricted and projected Aduhelm spending fell, Medicare’s 2023 Part B premium decreased.

The controversy highlighted an uncomfortable truth: coverage decisions for extremely expensive treatments can affect not only the patient receiving a drug but also premiums, state budgets, taxpayers, and resources available for other services.

Sources:

Why the FDA approval process became controversial

Aduhelm’s approval prompted investigations and criticism from physicians, researchers, lawmakers, and health-policy experts. Several members of the FDA advisory committee resigned after the agency approved the drug despite the committee’s negative assessment of the clinical evidence.

A December 2022 congressional staff report concluded that the FDA’s review process involved atypical interactions with Biogen and that the agency did not consistently follow its own documentation and communication procedures. The report also criticized Biogen’s pricing and launch strategy.

A later review by the Department of Health and Human Services Office of Inspector General examined the FDA’s use of accelerated approval across multiple drugs and identified concerns about documentation and agency procedures in several cases. Aduhelm became the best-known example in a broader debate over how surrogate endpoints, confirmatory trials, and regulatory flexibility should be handled.

None of this erased the desperate need for better Alzheimer’s treatment. Instead, it demonstrated why hope and evidence must travel together. Hope without evidence can become expensive disappointment; evidence without urgency can leave families waiting while the disease advances.

Sources:

What ultimately happened to Aduhelm?

In January 2024, Biogen announced that it would discontinue Aduhelm’s development and commercialization and terminate the required ENVISION confirmatory trial. The company said the decision reflected a reprioritization of resources rather than a newly identified safety or efficacy problem.

Commercial access ended during 2024. The FDA now lists Aduhelm’s accelerated-approval indication as withdrawn effective November 1, 2024. It is therefore no longer an FDA-approved or available treatment in the United States.

Meanwhile, the anti-amyloid field continued moving. Leqembi, or lecanemab, received traditional FDA approval in 2023, and Kisunla, or donanemab, received FDA approval in 2024. Both are intended for selected patients with early symptomatic Alzheimer’s disease and carry their own eligibility requirements, monitoring needs, safety concerns, and Medicare coverage conditions.

Patients should not assume that a previous Aduhelm evaluation automatically qualifies them for another therapy. A specialist may need to confirm the stage and cause of cognitive impairment, establish amyloid pathology, review MRI findings, assess medications such as anticoagulants, discuss genetic risk factors, and compare expected benefits with possible harms.

Sources:

What the Aduhelm episode changed

Aduhelm’s commercial life was brief, but its policy impact was enormous. The treatment forced regulators, insurers, clinicians, and the public to confront several questions that will return whenever an expensive therapy receives approval based on incomplete evidence.

FDA approval and insurance coverage are separate decisions

A regulator asks whether a medicine can be marketed. An insurer asks whether the available evidence supports payment for a particular population, setting, and use. Those decisions may overlap, but they are not interchangeable.

Surrogate endpoints must eventually connect to patient outcomes

Removing amyloid plaques is biologically measurable. Families, however, care about whether a person can recognize loved ones, manage basic routines, communicate, remain independent, and enjoy more good days. Confirmatory trials are essential because a laboratory or imaging change is valuable only when it reliably predicts a meaningful clinical benefit.

Access involves more than paying for the vial

Advanced Alzheimer’s treatments require diagnostic expertise, infusions, repeated imaging, emergency planning, and long-term follow-up. A coverage policy that ignores this supporting infrastructure may look generous on paper while remaining unreachable in practice.

Evidence collection should include representative patients

Older adults often have multiple health conditions, use numerous medications, and face transportation or caregiving limitations. Clinical studies and registries must include diverse populations so that physicians understand how treatments perform outside highly controlled research centers.

Experiences from the coverage controversy: what families and clinicians faced

The following examples are realistic composite scenarios based on commonly reported challenges. They do not describe specific identifiable patients.

A family discovers that “FDA approved” does not mean “Medicare covered”

Imagine a 72-year-old retired teacher who has recently been diagnosed with mild cognitive impairment caused by Alzheimer’s disease. Her daughter reads that the FDA has approved the first new Alzheimer’s treatment in years. The family arrives at the neurology appointment expecting to discuss a prescription.

Instead, the neurologist explains that Medicare will pay for Aduhelm only through a qualifying randomized clinical trial. The closest participating center is several hours away, enrollment is limited, and the patient may not qualify because of findings on her MRI. The family leaves with several brochures, three new acronyms, and the emotional equivalent of a flat tire.

The frustration is understandable. From the family’s perspective, approval sounded like access. From Medicare’s perspective, the evidence was too uncertain to support routine nationwide payment. Both ideas could be true at the same time, which did not make the conversation any easier.

A dual-eligible beneficiary encounters two complicated systems

Consider another patient who has both Medicare and Medicaid. His caregiver assumes Medicaid will cover the treatment if Medicare declines. The clinic’s billing team must explain that Medicare is generally the primary payer for the infusion and that Medicaid does not simply replace Medicare when a service falls outside a national coverage determination.

The caregiver then contacts the state Medicaid office, the managed-care plan, the neurologist, and the infusion center. Each organization answers a different part of the question. Nobody is necessarily giving incorrect information, but the family must assemble the pieces like a 1,000-piece puzzle printed entirely in beige.

This experience illustrates why coverage policy must be paired with plain-language navigation. A technically precise rule offers little comfort when a caregiver cannot determine who is responsible for the next step.

A specialist weighs hope against safety

Neurologists faced a different burden. Some patients urgently wanted any treatment that might slow decline. Physicians, however, had to explain that Aduhelm was not a cure, would not restore lost memories, and had uncertain clinical benefits. They also had to discuss ARIA, infusion schedules, MRI monitoring, and the possibility of pausing or ending treatment.

A physician could support research into anti-amyloid therapy while still believing that Aduhelm’s evidence was insufficient for routine use. That distinction was sometimes lost in public debate, where every opinion seemed to be sorted into either “for hope” or “against progress.” Clinical medicine is rarely that tidy.

Rural access creates another layer of restriction

For a patient living in a rural county, trial participation might require repeated long-distance travel. A single infusion could mean a full day away from home, transportation expenses, time off work for a caregiver, and another trip for MRI monitoring.

Even with insurance coverage, these practical costs can make treatment inaccessible. The Aduhelm experience showed that equitable access requires more than a national payment rule. It requires trained specialists, imaging capacity, infusion centers, reliable transportation, and support for caregivers.

The lasting experience is one of cautious progress

For many families, Aduhelm brought a rapid cycle of excitement, confusion, restricted access, and disappointment. Yet the scientific work did not disappear. The drug helped open a new era of amyloid-targeting treatments and pushed policymakers to build systems for registries, safety monitoring, and evidence-based coverage.

The most useful lesson is neither “approve everything” nor “cover nothing until certainty is perfect.” It is that patients deserve transparent evidence, realistic descriptions of benefit, careful safety protections, affordable access, and clear explanations of what an approval or coverage decision actually means.

Conclusion

Medicare’s restrictions on Aduhelm were not a routine cost-control decision. They represented an extraordinary response to an extraordinary approval: a high-priced treatment authorized through the accelerated pathway despite conflicting clinical results and significant uncertainty about patient benefit.

Medicaid’s role was less uniform. State programs generally had coverage obligations but retained tools such as prior authorization and clinical criteria, while complicated coordination rules affected people enrolled in both Medicare and Medicaid.

Aduhelm has now been discontinued, its FDA approval has been withdrawn, and newer anti-amyloid treatments have moved into clinical practice. Nevertheless, the central debate remains very much alive. How much evidence should be required before public insurance pays for an expensive new treatment? How should uncertainty be communicated to families? And how can health systems collect better evidence without turning patients into unpaid administrators of their own coverage?

Aduhelm did not provide the final answer to Alzheimer’s disease. It did, however, change the questions that regulators, insurers, researchers, and families will ask about every major treatment that follows.